These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 9752821)

  • 1. Tolcapone and fulminant hepatitis.
    Assal F; Spahr L; Hadengue A; Rubbia-Brandt L; Burkhard PR
    Lancet; 1998 Sep; 352(9132):958. PubMed ID: 9752821
    [No Abstract]   [Full Text] [Related]  

  • 2. Tolcapone-related fulminant hepatitis: electron microscopy shows mitochondrial alterations.
    Spahr L; Rubbia-Brandt L; Burkhard PR; Assal F; Hadengue A
    Dig Dis Sci; 2000 Sep; 45(9):1881-4. PubMed ID: 11052337
    [No Abstract]   [Full Text] [Related]  

  • 3. Neuroleptic malignant-like syndrome and acute hepatitis during tolcapone and clozapine medication.
    Blum MW; Siegel AM; Meier R; Hess K
    Eur Neurol; 2001; 46(3):158-60. PubMed ID: 11598337
    [No Abstract]   [Full Text] [Related]  

  • 4. Tolcapone-related liver dysfunction: implications for use in Parkinson's disease therapy.
    Borges N
    Drug Saf; 2003; 26(11):743-7. PubMed ID: 12908845
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tolcapone and hepatotoxic effects. Tasmar Advisory Panel.
    Olanow CW
    Arch Neurol; 2000 Feb; 57(2):263-7. PubMed ID: 10681087
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tolcapone and neurotoxicity in Parkinson's disease.
    Kuhn W; Woitalla D; Gerlach M; Russ H; Müller T
    Lancet; 1998 Oct; 352(9136):1313-4. PubMed ID: 9788488
    [No Abstract]   [Full Text] [Related]  

  • 7. Tolcapone (Tasmar).
    Robertson S
    CMAJ; 1999 Apr; 160(7):1052, 1056. PubMed ID: 10207353
    [No Abstract]   [Full Text] [Related]  

  • 8. Catechol-O-methyltransferase inhibitors in Parkinson's disease.
    Henry C; Wilson JA
    Lancet; 1998 Jun; 351(9120):1965-6. PubMed ID: 9654299
    [No Abstract]   [Full Text] [Related]  

  • 9. Tolcapone: new drug. In Parkinson's disease: unacceptable risk of severe hepatitis.
    Prescrire Int; 2006 Apr; 15(82):54-7. PubMed ID: 16604736
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tolcapone for Parkinson's disease.
    Med Lett Drugs Ther; 1998 Jun; 40(1028):60-1. PubMed ID: 9629124
    [No Abstract]   [Full Text] [Related]  

  • 11. Real-life evaluations of compliance with mandatory drug safety monitoring exemplified with tolcapone in Parkinson's disease.
    Unger MM; Reese JP; Oertel WH; Eggert KM
    Eur Neurol; 2008; 60(3):122-6. PubMed ID: 18628629
    [TBL] [Abstract][Full Text] [Related]  

  • 12. European Union directives on medicinal products found to be seriously defective.
    Griffin JP
    Adverse Drug React Toxicol Rev; 1999 Mar; 18(1):3-4. PubMed ID: 10401519
    [No Abstract]   [Full Text] [Related]  

  • 13. Detection of tolcapone in the cerebrospinal fluid of parkinsonian subjects.
    Russ H; Müller T; Woitalla D; Rahbar A; Hahn J; Kuhn W
    Naunyn Schmiedebergs Arch Pharmacol; 1999 Dec; 360(6):719-20. PubMed ID: 10619191
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Switch-over from tolcapone to entacapone in severe Parkinson's disease patients.
    Onofrj M; Thomas A; Iacono D; Di Iorio A; Bonanni L
    Eur Neurol; 2001; 46(1):11-6. PubMed ID: 11455177
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety and tolerability of adjunctive tolcapone treatment in patients with early Parkinson's disease.
    Lees AJ; Ratziu V; Tolosa E; Oertel WH
    J Neurol Neurosurg Psychiatry; 2007 Sep; 78(9):944-8. PubMed ID: 17098835
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Tolcapone: a different, effective approach to improving dopaminergic treatment in Parkinson's disease].
    Kulisevsky J
    Neurologia; 1998 Feb; 13(2):74-82. PubMed ID: 9578674
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Comparison of the safety of the medicinal product in the European Union and the United States, tolcapone (Tasmar) -- COMT inhibitor as the analyzed example].
    Konopka M; Członkowski A
    Neurol Neurochir Pol; 2005; 39(6):490-6. PubMed ID: 16355307
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tolcapone added to levodopa in stable parkinsonian patients: a double-blind placebo-controlled study. Tolcapone in Parkinson's Disease Study Group II (TIPS II).
    Dupont E; Burgunder JM; Findley LJ; Olsson JE; Dorflinger E
    Mov Disord; 1997 Nov; 12(6):928-34. PubMed ID: 9399217
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Akathisia secondary to tolcapone. Report of a case].
    Colorado-Ochoa H
    Gac Med Mex; 2000; 136(5):505-9. PubMed ID: 11080934
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of tolcapone on the haemodynamic effects and tolerability of desipramine.
    Jorga KM; Fotteler B; Modi M; Rabbia M
    Eur Neurol; 2000; 44(2):94-103. PubMed ID: 10965161
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.